

Pavblu[™] (aflibercept-ayyh) – New biosimilar launch

- On October 30, 2024, <u>Amgen launched Pavblu (aflibercept-ayyh)</u>, biosimilar to Regeneron's <u>Eylea[®] (aflibercept)</u>.
 - Pavblu is available as a 2 mg (0.05 mL of 40 mg/mL) solution in a single-dose vial and single-dose prefilled syringe.
- The <u>FDA approved</u> Pavblu in August 2024 for the treatment of:
 - Neovascular (wet) age-related macular degeneration
 - Macular edema following retinal vein occlusion
 - Diabetic macular edema
 - Diabetic retinopathy.
- Eylea is also approved for the treatment of retinopathy of prematurity.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.